Although both RTT and MDS are caused by alterations in MeCP2 dosage and share overlapping clinical features such as intellectual disability, epilepsy, and motor dysfunction, they exhibit distinct clinical courses. The gene discussed is MECP2; the disease is myelodysplastic syndrome.